FDA Approves Supplemental Application for Butrans by KNOA Pharma
The FDA has approved a supplemental application for Butrans, which contains buprenorphine as the active ingredient.
Asset / Drug
Drug and asset intelligence for Butrans with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Topline Data
June 27, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.